Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma

Completed · Not applicable

Conditions studied: Diffuse Large B-cell Lymphoma

In brief

This study will evaluate whether a reduction in the radiation dose and field size will maintain a high rate of local control while minimizing the risk of acute and late toxicity. Hypothesis- The radiation dose and treatment volume can be safely reduced from 30 Gy to 20 Gy while maintaining high rates of local control in patients who had a negative PET scan following rituximab-containing chemotherapy.

Key facts

Study ID

NCT01186978

Run by

Duke University

People needed

63

Starts

2010-09-20

Expected to finish

2019-06-04

Last updated by the study team

2020-06-02

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologic documentation of diffuse large B-cell lymphoma, or any of its variants as defined in the WHO classification
• Completion of at least 4 cycles of a rituximab-containing, anthracycline-based combination chemotherapy
• Negative post-chemotherapy (or interim) PET scan
• Absolute neutrophil count greater than 1500 and platelet count greater than 40,000
• Negative pregnancy test in women of child-bearing potential
• For patients with HIV/AIDS, the following must be true:
• The patient is compliant on combination anti-retroviral therapy (CART)
• The patient has CD4 count ≥ 200 at time of diagnosis

You may not qualify if…

• Any contraindications to irradiation
• Primary CNS lymphoma
• HIV/AIDS

Where it is running

• Durham Regional Hospital — Durham, North Carolina, United States
• Duke University Medical Center — Durham, North Carolina, United States
• Duke Raleigh Hospital — Raleigh, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.